Thomas E. Delea, Arati Sharma, Aaron Grossman, Caitlin Eichten, Keenan Fenton, Neil Josephson, Akshara Richhariya & Alison J. Moskowitz. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ. 2018 Oct 30:1-25. doi: 10.1080/13696998.2018.1542599. [Epub ahead of print] - PAI - Policy Analysis Inc.

Thomas E. Delea, Arati Sharma, Aaron Grossman, Caitlin Eichten, Keenan Fenton, Neil Josephson, Akshara Richhariya & Alison J. Moskowitz. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ. 2018 Oct 30:1-25. doi: 10.1080/13696998.2018.1542599. [Epub ahead of print] - PAI - Policy Analysis Inc.